Abstract
Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1963-1967 |
| Number of pages | 5 |
| Journal | Angewandte Chemie - International Edition |
| Volume | 53 |
| Issue number | 7 |
| DOIs | |
| State | Published - Feb 10 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- antitumor agents
- drug design
- inflammation
- platinum
- prodrugs
ASJC Scopus subject areas
- Catalysis
- Chemistry(all)
Cite this
The prodrug platin-A : Simultaneous release of cisplatin and aspirin. / Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta.
In: Angewandte Chemie - International Edition, Vol. 53, No. 7, 10.02.2014, p. 1963-1967.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The prodrug platin-A
T2 - Simultaneous release of cisplatin and aspirin
AU - Pathak, Rakesh K.
AU - Marrache, Sean
AU - Choi, Joshua H.
AU - Berding, Trenton B.
AU - Dhar, Shanta
PY - 2014/2/10
Y1 - 2014/2/10
N2 - Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.
AB - Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug. The prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the side effects of cisplatin. Platin-A exhibits anticancer and anti-inflammatory properties which are better than those for the combined use of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered as a single prodrug.
KW - antitumor agents
KW - drug design
KW - inflammation
KW - platinum
KW - prodrugs
UR - http://www.scopus.com/inward/record.url?scp=84893537386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893537386&partnerID=8YFLogxK
U2 - 10.1002/anie.201308899
DO - 10.1002/anie.201308899
M3 - Article
C2 - 24453035
AN - SCOPUS:84893537386
VL - 53
SP - 1963
EP - 1967
JO - Angewandte Chemie - International Edition
JF - Angewandte Chemie - International Edition
SN - 1433-7851
IS - 7
ER -